almagate has been researched along with Eye Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alves, C; Batel Marques, F; Mendes, D; Penedones, A | 1 |
| Drolet, DW; Gold, L; Green, LS; Janjic, N | 1 |
| Kocabora, MS; Ozbilen, KT; Serefoglu, K | 1 |
| Acquah, K; Day, S; Grossman, DS; Lee, PP; Mruthyunjaya, P; Sloan, FA | 1 |
| Grabska-Liberek, I; Jamrozy-Witkowska, A; Jankowska-Lech, I; Kowalska, K; Nowosielska, A; Terelak-Borys, B | 1 |
| Adamis, AP; Calias, P; Cunningham, ET; Guyer, DR; Ng, EW; Shima, DT | 1 |
| Ballas, ZK; Hare, ND | 1 |
| Kompella, UB | 1 |
3 review(s) available for almagate and Eye Diseases
| Article | Year |
|---|---|
Safety monitoring of ophthalmic biologics: a systematic review of pre- and postmarketing safety data.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Biological Products; Eye Diseases; Humans; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Pigment Epithelium; Thromboembolism; Vascular Endothelial Growth Factor A | 2014 |
Fit for the Eye: Aptamers in Ocular Disorders.
Topics: Aptamers, Nucleotide; Eye Diseases; Humans; Ligands; Ophthalmology; SELEX Aptamer Technique | 2016 |
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Clinical Trials as Topic; Diabetic Retinopathy; Drug Delivery Systems; Eye; Eye Diseases; Humans; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2006 |
5 other study(ies) available for almagate and Eye Diseases
| Article | Year |
|---|---|
Intravitreal silicone oil droplets following pegaptanib injection.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Eye Diseases; Eye Foreign Bodies; Humans; Injections; Mass Spectrometry; Silicon; Silicone Oils; Ultrasonography; Vascular Endothelial Growth Factor A; Vitreous Body | 2010 |
Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Case-Control Studies; Endophthalmitis; Eye Diseases; Female; Follow-Up Studies; Health Services Research; Humans; Incidence; Intravitreal Injections; Macular Degeneration; Male; Medicare Part B; Proportional Hazards Models; Ranibizumab; Retinal Detachment; Retinal Perforations; Retrospective Studies; United States; Uveitis; Vascular Endothelial Growth Factor A; Vitreous Hemorrhage | 2011 |
[Complications of intravitreal injections--own experience].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctival Diseases; Diabetic Retinopathy; Endophthalmitis; Eye Diseases; Eye Hemorrhage; Female; Follow-Up Studies; Glucocorticoids; Humans; Inflammation; Intravitreal Injections; Iris Diseases; Macular Degeneration; Macular Edema; Male; Middle Aged; Ocular Hypertension; Poland; Ranibizumab; Retinal Diseases; Retinal Vein Occlusion; Retrospective Studies; Risk Factors; Triamcinolone Acetonide; Visual Acuity | 2011 |
Effectiveness of delayed epinephrine in anaphylaxis.
Topics: Aged, 80 and over; Anaphylaxis; Anticoagulants; Aptamers, Nucleotide; Bronchodilator Agents; Cardiovascular Diseases; Epinephrine; Eye Diseases; Heart Transplantation; Heparin; Humans; Injections, Intramuscular; Male; Middle Aged; Time Factors | 2007 |
Drug delivery to the back of the eye.
Topics: Antiviral Agents; Aptamers, Nucleotide; Clinical Trials, Phase III as Topic; Drug Administration Routes; Drug Delivery Systems; Eye Diseases; Glaucoma; Humans; Injections; Macular Degeneration; Nanoparticles; Oligonucleotides, Antisense; Ophthalmic Solutions; Retinal Diseases; Thionucleotides; Vascular Endothelial Growth Factor A | 2007 |